Inhibition of 12/15 lipoxygenase by curcumin and an extract from Curcuma longa L.

Ceska a Slovenska Farmacie

Volumn 63, Issue 1, 2014, Pages 26-31

  Bezáková, Lýdia ^a   Košt'Álová, Daniela ^b   Obložinský, Marek ^a   Hoffman, Peter ^a   Pekárová, Mária ^a   Kollárová, Renáta ^a   Holková, Ivana ^a   Mošovská, Silvia ^b   Šturdík, Ernest ^b  

^a Faculty of Natural Sciences   (Slovakia)

^b SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

Author keywords

Curcuma longa L.; Curcumin; Linoleic acid; Lipoxygenase inhibition; Turmeric extract

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONIC ACID; CURCUMA LONGA EXTRACT; CURCUMIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; LIPOXYGENASE; 12-15-LIPOXYGENASE;

ANIMAL TISSUE; ARTICLE; CURCUMA LONGA; CYTOSOL; CYTOSOLIC FRACTION; ENZYME ISOLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; KINETICS; MALE; NONHUMAN; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RHIZOME; ULTRAVIOLET SPECTROPHOTOMETRY; ANIMAL; CHEMISTRY; CURCUMA; DRUG EFFECTS; ISOLATION AND PURIFICATION; WISTAR RAT; ANIMAL CELL; COMPETITIVE INHIBITION; DRUG DETERMINATION; DRUG SPECIFICITY; ENZYME INHIBITION; IC50; PROTEIN EXPRESSION;

ANIMALS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; ARACHIDONIC ACID; CURCUMA; CURCUMIN; MALE; RATS; RATS, WISTAR; RHIZOME;

EID: 84901052795     PISSN: 12107816     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jayaprakasha G. K., Jagan L., Rao M., Sakariah K. K. Chemistry and biological activities of C. longa. Trends in Food Science Technology 2005; 16, 533-548. (Pubitemid 41674487)
2. Gupta S. C., Prasad S., Kim J. H., Patchva S., Webb L., Priyadarsini I. K., Aggarwal B. B.Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep. 2011; 28, 1937-1953.
3. Ak T., Gúlcin I. Antioxidant and radical scavenging properties of curcumin. Chemico-Biological Interaction 2008; 174, 27-37.
4. Basnet P., Skalko-Basnet N. Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 2011; 16, 4567-4598.
5. Shehzad A., Khan S., Shehzad D., Lee Y. S. Curcumin therapeutic promises and bioavailability in colorectal cancer. Drug Today 2010; 47(7), 523-532.
6. Caroll R. E., Bena R. V., Turgeon D. K., Varee S., et al. Phase II clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev. Res. 2011; 4(3), 354-364.
7. Shureiqi I., Baron J. A. Curcumin Chemoprevention: The long road to clinical translation. Cancer Prev. Res. 2011; 4(3), 296-298.
8. Ammon H. P., Safayhi H., Mack T., Sabieraj J. Mechanism of anti-inflammatory actions of curcumine and boswellic acids. J Ethnopharmacol. 1993; 38(2-3): 113-119. (Pubitemid 23136055)
9. Kohll K., All J., Ansari J., Raheman Z. Curcumin: A natural antiinflammatory agent. Indian J. Pharmacol. 2005; 37(3), 141-147. (Pubitemid 40898222)
10. Jankun L., Aleem A. M., Malgorzewicz S., Szkudlarek M., Zavodszky M. I., Devitt D. L., Feig M., Selman S. H., Skrzypczak-Jankun E. Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells. Mol. Cancer Ther. 2006; 5(5), 1371-1382. (Pubitemid 43881331)
11. Wu J., Xiang Xia H. H., Ping Tu S., Fan D. M., Lin M. Ch., Kung H. F., Lam S. K., Wong B. Ch. 15-lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. Carcinogenesis. 2003; 24(2), 243-247. (Pubitemid 36267092)
12. Segraves S., WaltherM , Ivanov I., et al. Sequence determinants for the reaction specificity of murine (12R)-lipoxygenase: Targeted substrate modification and site-directed mutagenesis. J. Biol. Chem. 2005; 280, 36633-36641. (Pubitemid 41587740)
13. Werz O., Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol. Therapeut. 2006; 112: 701-718. (Pubitemid 44592614)
14. Montuschi P., Sala A., Dahlén S. E., Folco G. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov. Today 2007; 12, 404-412. (Pubitemid 46636374)
15. Wen Y., Gu J., Vandenhoff G. E., Liu X, Nadler J. L. The role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages. Am. J. Physiol. Heart Circ. Physiol. 2008; 294, H1933-H1938.
16. Chakrabarti S. K, Cole B. K, Wen Y., Keller S. R., Nadler J. L. 12/15-lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity 2009; 17, 1657-1663.
17. Yuan H., Lanting L., Xu Z. G., Li S. L., Swiderski P., Putta S., JonnalagaddaM., KatoM., Natarajan R. Effects of cholesteroltagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am. J. Physiol-Renal 2008; 295, F605-F617.
18. Martínez-ClementeM., Ferré N., Titos E., Horrilo R., González-Périz A., Morán-Salvador E., López-Vicario C., Miquel R., Arroyo V., Funk C. D., Claria J. Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. Hepatology 2010; 52, 1980-1991.
19. Krönke G., Katzenbeisser J., Uderhardt S., Zaiss M. M., Scholtysek C., Schabbauer G., Zarbock A., Koenders M. I., Axmann R., Baencler H. W, Van Den Berg W., Voll R. E., Kuhn H., Joosten L. A., Schett G. 12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. J. Immunol. 2009; 183, 3383-3389.
20. Rossaint J., Nadler J. L., Ley K., Zarbock A. Eliminating or blocking 12/15-lipoxygenase reduces neutrophil recruitment in mouse models of acute lung injury. Crit. Care 2012; 16, R166.
21. Kulkarni A. P., Cai Y., Richards I. S. Rat pulmonary lipoxygenase: Dioxygenase activity and role in xenobiotic metabolism. Int. J. Biochem. 1992; 24, 255-261.
22. BradfordM.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal. Biochem. 1976; 72, 248-254.
23. Kemal C., Louis-Flamberg P., Krupinski-Olsen R., Shorter A. R. Reductive inactivation of soybean lipoxygenase 1 by catechols: A possible mechanism for regulation of lipoxygenase activity . Biochemistry. 1987; 26, 7064-7068.
24. Hoffman P., Rauová D., Bezáková L., ObloÏinsk M., Mikuš P. HPLC method for determination of lipoxygenase positional specific products. J. Pharm. Biomed. Anal. 2013; 84, 53-58.
25. Aggarwal B., Harikumar K. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. & Cell Biol. 2009; 41, 40-59.
26. Lev-Ari S., Strier L., Kazanov D., Shapiro L. M., Sobol H. D., Pinchuk I., Marian B., Lichtenberg D., Arber N. Celecoxib and curcumin synergistically inhibit the growth of colerectal cancer cells. Clin. Cancer Res. 2005; 11, 6738.
27. Basnet P., Skalko-Basnet N. Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011; 16, 4567-4598.
28. Caroll R. E., Bena R. V., Turgeon D. K., Varee S., et al. Phase II clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev. Res. 2011; 4(3), 354-364.
29. Gupta S. C., Prasad S., Kim J. H., Patchva S., Webb L., Priyadarsini I. K., Aggarwal B. B.Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep. 2011; 28, 1937-1953.
30. Shureiqi I., Baron J.A. Curcumin Chemoprevention: The long road to clinical translation. Cancer Prev. Res. 2011; 4(3), 296-298.
31. Began G., Sudharshan E., Appu Rao A. G. Inhibition of lipoxygenase 1 by Phospatidylcholine micelles-bound curcumin. Lipids. 1998; 33(12), 1223-1228. (Pubitemid 29061889)
32. Skrzypczak-Jankun E., McCabe N. P., Selman S. H., Jankun J. Curcumin inhibits lipoxygenase by binding to its central cavity: Theoretical and X-ray. evidence. Int°. J. Mol. Med. 2000; 6, 521-526.
33. Hajek A. R., Lindley A. R., Favoreto S., Carter R., Schleime R. P., Kuperman, D. A. 12/15-lipoxygenase deficiency protects mice from allergic airways inflammation and increases secretory IgA levels. J. Allergy Clin. Immunol. 2008; 122, 633-639.
34. Zarbock A., DistasiM. R., Smith E., Sanders J.M., Kronke G., Hardy B. L., Vietinghoff S. Improved survival and reduced vascular permeability by eliminating or blocking 12/15-lipoxygenase in mouse models of acute lung injury (ALI). J. Immunol. 2009; 183, 4715-4722.
35. Kawakami Y., Hosokawa T., Morinaka T., Irino S., Hirano S., Kobayashi H., Yoshioka A., Suzuki-Yamamoto T., Yokoro M., Kimoto M., Tsuji H., Yamashita H., Doi S., Yutani C., Kato R., Itabe H., Kanada T., Hada T., Takahashi Y. Antiatherogenic effect of guava leaf extracts inhibiting leukocyte-type 12-lipoxygenase activity. Food Chem. 2012; 131, 1069-1075.
36. Rong S., Cao Q., Liu M., Seo J., Lia L., Boudyguina E., Gebre R. K. Macrophage 12/13 lipoxygenase expression increases plasma and hepatic lipid levels and extracerebrates atherosclerosis. J. Lipid Res. 2012; doi: 10.1194/jlr. MO22723.
37. Huo Y., Zhao L., Hyman M. C., Shashkin P., Harry B. L., Burcin T., Forlow S. B., Stark M. A., Smidth D. F., Clarke S. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 110, 2024-2031. (Pubitemid 39331917)